Continuous - Time Markov Modeling of Durvalumab Dynamics after Chemoradiotherapy in Stage III NSCLC (PACIFIC Era): Development, Validation, and Extrapolation
Background: Immunotherapy in un-resectable stage III NSCLC shows delayed treatment effects and time-varying hazards that challenge proportional-hazards assumptions. We developed a Continuous-Time Markov Chain (CTMC) model - with piecewise hazards - to capture the temporal…...
10.5281/zenodo.19763230